Home » Research » Publications

Publications by members of the Bill Walsh Lab:


Hioki T, Gholami YH, McKelvey KJ, Aslani A, Marquis H, Eslick EM, Willowson KP, Howell VM, Bailey DL. Overlooked potential of positrons in cancer therapy. Scientific Reports. 2021, 11, 2475

Zakarya RChan YLRutting S, et al BET proteins are associated with the induction of small airway fibrosis in COPD 

Prasahanth A, Donaghy H, Stoner S, Hudson A, Diakos C, Howell V, Grau G, McKelvey K. Are in vitro human blood-brain-barriers suitable replacements for in vitro models of brain permeability for novel therapeutics? 2021. Cancers (BaseL). 13(5):955

McKelvey KJ, Wilson EB, Short S, Melcher A, Diakos CI, Howell VM. Glycolysis and fatty acid oxidation inhibition improves survival in glioblastoma. 2020. Frontiers in Oncology – Cancer Metabolism. 2021. Accepted.

Sahni S, Pandya AR, Hadden WJ, Nahm C, Maloney S, Cook V, Toft JA, Wilkinson-White L, Gill AJ, Samra JS, Dona A and Mittal A. A Unique Urinary Metabolomic Signature for the Detection of Pancreatic Ductal Adenocarcinoma. Int J Cancer 2021;148(6):1508-18. doi: 10.1002/ijc.33368.

Nahm C, Alzaabi S, Sahni S, Gill AJ, Samra J, Mittal A. Increased postoperative pancreatic fistula rate after distal pancreatectomy compared with pancreatoduodenectomy is attributable to a difference in acinar scores. Journal of Hepato-Biliary-Pancreatic Sciences 2021 (doi: 10.1002/jhbp.934; PMID: 33665934)

Daniel J. Klinosky…. Sahni, S; Janssen, P.J... et al. (Consortium of Researchers). Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy (4th edition). Autophagy 2021;1-382.

Angela Chou, Mahsa Ahadi, Jennifer Arena, Loretta Sioson, Amy Sheen, Talia L Fuchs, Nicholas Pavlakis, Stephen Clarke, Sumit Sahni, Anubhav Mittal, Jaswinder Samra, Anthony J Gill. A critical assessment of post neoadjuvant pancreatic cancer regression grading schemes with a proposal for a novel approach. American J Surgical Pathology 2021;45(3):394-404.

Matthew B O’Rourke, Sumit Sahni, Jaswinder Samra, Anubhav Mittal, Mark P. Molloy. Data Independent Acquisition of plasma biomarkers of response to Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma. J Proteomics 2021;231:103998.


Krishan, S., Sahni, S and Richardson, D.R*. The anti-tumor agent, Dp44mT, promotes nuclear translocation of TFEB via inhibition of the AMPK-mTORC1 axis. BBA Mol Basis Disease 2020;1866(12):165970.

Gillson, J.; Ramaswamy, Y.;  Singh, G.; Gorfe, A; Pavlakis, N; Samra, J; Mittal, A; Sahni,S. Small molecule KRAS inhibitors – the future for targeted pancreatic. Cancers 2020;12(5):1341.

Hadden, M; Mittal, A; Samra,J; Zreiqat,H; Sahni,S, Ramaswamy,Y. Mechanically Stressed Cancer Microenvironment: Role in Pancreatic Cancer Progression. Biochim Biophys Acta Rev Cancer. 2020 1874:188418.

Sahni,S , Krisp,C; Molloy,M; Nahm, C; Gillson,J;  Gill, AJ: Samra,J and Mittal,A. PSMD11, PTPRM and PTPRB as Novel Biomarkers of Pancreatic Cancer Progression. Biophys. Acta -General Subjects 2020;1864(11):129682.

Stefan K, Leck LYW, Namasivayam V, Bascunana P, Huang MLH, Riss PJ, Pahnke J. Jansson PJ, *Stefan SM. Vesicular ATP-binding cassette transporters in human disease – relevant aspects of their organization for future drug development. Future Drug. Discov. 2020 Accepted September 29 (10.4155/fdd-2020-0025)

Lim SC, Jansson PJ, Stephen J. Assinder SJ, Sanaz M, Richardson DR, Kovacevic Z. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance. FASEB J., 2020; 177(10),2365-2380

Bae DH, Lane DJR, Siafakas AR, Sutak R, Paluncic J, Huang MLH, Jansson PJ, Rahmanto YS, Richardson DR. Acireductone dioxygenase 1 (ADI1) is regulated by cellular iron by a mechanism involving the iron chaperone, PCBP1, with PCBP2 acting as a potential co-chaperone. Biochim Biophys Acta Mol Basis Dis. 2020; 29:165844.

Sahni S, Gillson J, Park KC, Chiang S, Leck LYW, Jansson PJ, Richardson DR. NDRG1 suppresses basal and hypoxia-induced autophagy at both the initiation and degradation stages and sensitizes pancreatic cancer cells to lysosomal membrane permeabilization. Biochim Biophys Acta Gen Subj. 2020; 23:129625.

Stefan SM, Jansson PJ, Kalinowski DS, Anjum R, Dharmasivam M, Richardson DR. The growing evidence for targeting P-glycoprotein in lysosomes to overcome resistance. Future Med Chem. 2020; 12(6):473-477.

Fouani L, Huang MLH, Cole L,Jansson PJ, Kovacevic Z, Richardson DR. During mitosis ZEB1 “switches” from being a chromatin-bound epithelial gene repressor, to become a microtubule-associated protein. Biochim Biophys Acta Mol Cell Res. 2020;1867(7):118673.

Maqbool SN, Lim SC, Park KC, Hanif R, Richardson DR, Jansson PJ, *Kovacevic Z. Overcoming Tamoxifen-Resistance in Estrogen Receptor Positive Breast Cancer Using the Novel Thiosemicarbazone Anti-Cancer Agent, DpC. Br J Pharmacol. 2020;177(10):2365-2380

Krishan S, Sahni S, Leck LYW, Jansson PJ, Richardson DR. Regulation of autophagy and apoptosis by Dp44mT-mediated activation of AMPK in pancreatic cancer cells. Biochim Biophys Acta Mol Basis Dis. 2020;1866(5):165657.

Park KC, Geleta B, Leck LYW, Paluncic J, Chiang S, Jansson PJ, Kovacevic Z, Richardson DR. Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding. J Biol Chem. 2020;295(2):481-503.

Zakarya, R.; Howell, V.M. and Colvin, E.C. Modelling Epithelial Ovarian Cancer in Mice: Classical and Emerging Approaches. Int. J. Mol. Sci. 2020, 21(13), 4806

McKelvey,K.J.; Hudson,A.L; Kumar,R.P; Wilmott, J.S; Attrill, G.H.; Long, G.V.; Scolyer,R.A.; Clarke,S.J.; Wheeler,H.R.; Diakos,.C.I and Howell,V.M. Temporal and spatial modulation of the immune response of the murine Gl261 glioma tumor microenvironment. 2020. PLoS One. 15(4):e0226444

Deng,W; McKelvey,K.J; Guller, A; Fayzullin, A; Campbell, J; Clement, S; Habibalahi,A; Howell, V.M; Engel,A; Wargocka, Z; Liang,L; Chao, S and Goldys, E. Application of mitochondrially targeted nanoconstructs to neo-adjuvant X-ray-induced photodynamic therapy for rectal cancer. 2020. ACS Cent Sci 6(5):715

Colvin, E; Howell, V; Mok, S; Samimi, G; Vafaee, F(2020) Expression of lncRNAs in cancer-associated fibroblasts linked to patient survival in ovarian cancer. Cancer Science (accepted 7/2/20)

Alexander, M; Pavlakis, N; John, T; O’Connell, R; Kao, S; Hughes, B; Lee, A; Hayes, SA; Howell, VM; Clarke SJ; Millward, M; Burbury, K; Solomon B; Itchins, M. A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. Lung Cancer (In Press – 1st February 2020)

Sahni, S; Miller, E; Howell, VM; Mehta,S; Pavlakis,N; Chan,D; Ahadi,MS; Gill,AJ; Samra J and Mittal A. Tissue Biomarker Panel as a Surrogate Marker for Squamous Subtype of Pancreatic Cancer. European Journal of Surgical Oncology (In Press – 1st February 2020).

McKelvey KJ, Hudson AL, Prasanna Kumar R, Eade T, Clarke SJ, Wheeler HR, Diakos CI and Howell VM (2020) Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer. Front. Oncol. 9:1504. doi: 10.3389/fonc.2019.01504

Gholami, Y.H. , Josephson L, Akam EA, Caravan P, Wilks MQ, Pan X-Z, Maschmeyer R, Kolnick A, El Fakhri G, Normandin MD, Kuncic  Z and Yuan H. A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Therapeutic Isotopes. Int J Nanomedicine. January 2020 Volume 2020:15 Pages 31—47


Gholami, Y.H., Maschmeyer, R. & Kuncic, Z. Radio-enhancement effects by radiolabeled nanoparticles. Sci Rep 9, 14346 2019 doi:10.1038/s41598-019-50861-2

Nahm CBItchins M, Arena J, Colvin E, Howell VM, Pavlakis N, Clarke S, Samra JS, Gill AJ, Mittal A. 2019 Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study. Eur J Surg Oncol. Feb;45(2):218-224. doi: 10.1016/j.ejso.2018.10.050.

Lee A, Arasaratnam M, Chan DLH, Khasraw M, Howell VM, Wheeler H, J Platt. 2019 Anti‐epidermal growth factor receptor therapy for glioblastoma in adults. Cochrane Database of Systematic Reviews 2019, Issue 1,


Behren A, Speidel D, Kollias G, Howell VM. Introduction to Mammalian Genome special issue: inflammation and immunity in cancer. Mamm Genome. 2018 Nov 2. doi: 10.1007/s00335-018-9787-y.

Rath EM, Cheng YY, Pinese M, Sarun KH, Hudson AL, Weir C, Wang YD, Hakansson AP, Howell VM, Liu GJ, Reid G, Knott RB, Duff AP and Church WB (2018), BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state. PLOS ONE Aug 29;13(8):e0203003.

Lee A, Howell VM, Itchins M, Wheeler HR, Pavlakis N. (2018). ROS1-rearranged NSCLC, Factor V Leiden and recurrent venous thrombosis. Clinical Lung Cancer Jun 5. pii: S1525-7304(18)30135-9. doi: 10.1016/j.cllc.2018.05.015

Gholami YH, Willowson K, Forwood N, Harvie R, Hardcastle N, Bromley R, Ryu H, Yuen S, Howell VM, Kuncic Z, Bailey DL (2018). Comparison of radiobiological parameters for 90Y Radionuclide Therapy (RNT) and External Beam Radiotherapy (EBRT) in vitro, European Journal of Nuclear Medicine and Molecular Imaging – EJNMMI Physics; 2018 Sep 3;5(1):18. doi: 10.1186/s40658-018-0217-8.

McKelvey, K.J., Hudson, A.L., Back, M., Eade, T. and Diakos, C. (2018) Radiation and inflammation/immune response in cancer. Mammalian Genome, 29 (11-12), 843-865.

Hudson, A.L., Parker, N.R., Khong, P., Parkinson, J.F., Ikin, R.J., Zhu, Y., Wheeler, HR and Howell, V.M. (2018). Glioblastoma Recurrence Correlates with Increased APE1 and Polarisation Towards an Immuno-Suppressive Microenvironment. Frontiers in Oncology, 8:314.

Cho, A., McKelvey, K.J., Lee, A. and Hudson, A.L. (2018). The intertwined fates of inflammation and coagulation in glioma. Mammalian Genome, 29 (11-12), 806-816.

Chou A, Itchins M, de Reuver PR, Arena J, Clarkson A, Sheen A, Sioson L, Cheung V, Perren A, Nahm CB, Mittal A, Samra JS, Pajic M, Gill AJ. ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumours. Human Pathology. Dec;82:249-257. doi: 10.1016/j.humpath.2018.07.032. Epub 2018 Aug 3.

Hayes SA, Clarke S, Pavlakis N, Howell VM. The role of proteomics in the age of immunotherapies. Mamm Genome. 2018 Jul 25. doi: 10.1007/s00335-018-9763-6

Itchins M, Clarke S, Pavlakis N. Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?—the shifting paradigm of therapeutics. Transl Lung Cancer Res. 7(Suppl 1):S39-S4 2018

Bettison T, Nahm CB, Gill AJ, Mittal A, Malhi G, Samra JS. Understanding the pathophysiology of psychological distress and pancreatic cancer: A systematic review. Pancreas. 2018 Apr;47(4):376-381

Nahm CB, Connor S, Samra JS, Mittal AM. Post-operative pancreatic fistula: A review of traditional and emerging concepts. Clinical and Experimental Gastroenterology 2018:11;1-14

Nahm CB, Najdawi F, Reagh J, Kaufman A, Gill AJ, Mittal AM, Samra JS. Pancreatic hamartoma – A sheep in wolf’s clothing. ANZ Journal of Surgery. 2018 Jan 8. doi: 10.1111/ans.14332.

Nahm CB, Brown K, Townend P, Gill AJ, Howell V, Colvin E, Samra JS, Mittal A. Acinar and collagen content of the pancreatic neck margin predicts post pancreatectomy pancreatitis and clinically relevant pancreatic fistula. HPB 2018 Jan 5. doi: 10.1016/j.hpb.2017.11.003.

BTT Pham, EK Colvin, NTH Pham, BJ Kim, ES Fuller, EA Moon, R Barbey, S Yuen, BH Rickman,  NS Bryce, S Bickley, M Tanudji, SK Jones, VM Howell and BS Hawkett (2018). Biodistribution and Clearance of Stable Superparamagnetic Maghemite Iron Oxide Nanoparticles in Mice Following Intraperitoneal Administration. International Journal of Molecular Sciences, 2018, 19, 205

Hayes AR, Jayamanne D, Hsiao E, Schembri GP, Bailey DL, Roach PJ, Khasraw M, Newey A,Wheeler HR, Back M. (2018) Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma. Pract Radiat Oncol.  S1879-8500(18)30006-7. doi: 10.1016/j.prro.2018.01.006.


Itchins M, Chia PL, Hayes SAHowell VM, Gill AJ, Cooper WA, John T, Mitchell P, Millward M, Clarke SJ, Solomon B, Pavlakis N. Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context. Asia Pac J Clin Oncol. 2017 Aug;13 Suppl 3:3-13. doi: 10.1111/ajco.12754.

Itchins M, Ascerto PA, Menzies A, Oatley M, Lo S, Douraghi-Zadeh D, Harrington T, Maher R, Grimaldi AM, Guminski A. Sequential trans-arterial fotemustine chemotherapy (TAC) and checkpoint immunotherapy for uveal melanoma with hepatic metastases. Melanoma Research. 27(3); 2017

Wong E, Jones J, Gundara J, Nahm CB, Cho S, Norton I, Samra JS, Mittal AM. Minimally invasive necrosectomy versus open necrosectomy approaches in a tertiary hepatopancreaticobiliary unit. JOP J Pancreas. 2017 Sep 29;18(5):415-419

Kim S, Nahm CB, Gill AJ, Samra JS, Mittal A. Patterns and determinants of recurrence for pancreatic ductal adenocarcinoma after resection. JOP J Pancreas. 2017 Nov 30;18(6):458-464

Chua TC, Mittal AM, Nahm CB, Hugh TJ, Arena J, Gill AJ, Samra JS. Pancreatoduodenectomy in a public versus private teaching hospital outcomes are comparable with some minor variations. ANZ J Surg. 2017 Oct 5. doi: 10.1111/ans.14191.

Stephenson DP, Nahm CB, Chua TC, Gill AJ, Mittal A, De Reuver PR, Samra JS. Circulating and disseminated tumor cells in pancreatic cancer and their role in patient prognosis: a systematic review and meta-analysis. Oncotarget. 2017 Aug 4;8(63):107223-107236. doi: 10.18632/oncotarget.19928.

Itchins M, Pavlakis N. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A     Multinational Placebo-Controlled Phase II Trial Commentary Article. Translational Gastroenterology and Hepatology. 2(2); 2017

Itchins M, Arena J, Nahm CB, Rabindran J, Kim S, Gibbs E, S, Bergamin S, Chua TC, Gill AJ, Maher R, Diakos C, Wong M, Mittal A, Hruby G, Kneebone A, Pavlakis N, Samra J & Clarke S. Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre. Eur J Surg Oncol. 2017 Sep;43(9):1711-1717. doi: 10.1016/j.ejso.2017.06.012. Epub 2017 Jun 28.

Itchins M, Arena J, Pavlakis NNahm CB, Gibbs E, Mohamudally A, Maher R, Blome S, Mann G, Bailey L, Schembri, G, Gill AJ, Diakos C, Khasraw M, Hruby G, Kneebone A, Mittal A, Samra J, Clarke S. Pattern of Care and Survival of Pancreatic Ductal Adenocarcinoma in a Multi-Disciplinary High-Volume Centre. Journal of Pancreatic Research, Disorders and Therapy. 2017, 1(1):00005

Nahm CB, Cho S, Norton I, Gill AJ, Samra JS, Mittal A. Cystic Neoplasms of the Pancreas. Medicine Today 2017;18(4):55-61.

Nahm CB, de Reuver PR, Hugh TJ, Pearson A, Samra JS, Mittal A. Intra-operative amylase in peri-pancreatic fluid predicts pancreatic fistula after distal pancreatectomy. J Gastrointest Surg. 2017 Jun;21(6):1031-1037. doi: 10.1007/s11605-017-3395-0. Epub 2017 Mar 20.

Nahm CB, Mittal A, Gill AJ, Samra JS. Pancreatic Rheumatoid Nodule: Case Report and Review of the Literature. Pancreas. 2017 May/Jun;46(5):e45-e47. doi: 10.1097/MPA.0000000000000799

F Vafaee, E Colvin, S Mok, VM Howell, and G Samimi (2017) Functional prediction of long non-coding RNAs in ovarian cancer-associated fibroblasts indicate a potential role in metastasis. Scientific Reports (Nature) 2017 Sep 4;7(1):10374. doi: 10.1038/s41598-017-10869-y.

Byrne H. L., Gholami H Y and Kuncic Z. “Impact of fluorescence on nanoparticle enhancement of radiation dose – implications for gold nanoparticle radiosensitisation” Phys. Med. Biol., vol. 62, no. 8, p. 3097, 2017.

Capper D, von Deimling A, Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, Specenier P, Rodon J, Cleverly A, Smith C, Gueorguieva I, Miles C, Guba SC, Desaiah D, Estrem ST, Lahn MM, Wick W. (2017) Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. Int J Mol Sci. 18(5). pii: E995. doi: 10.3390/ijms18050995.PMID:28481241


Parker, N.R., Hudson, A.L.*, Khong, P., Parkinson, J.F., Dwight, T., Ikin, R.J., Zhu, Y., Cheng, Z.J., Vafaee, F., Chen, J., Wheeler, H.R. and Howell, V.M. (2016) Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma. Sci Rep, accepted (17th Feb). IF 5.578. *Joint 1st author.

Hudson, A.L. and Colvin, E.K. (2016) Transgenic mouse models of SV-40-induced cancer. ILAR journal, accepted (7th Jan). IF 2.393.

Howell VM and Davidson B. (2016) Epithelial ovarian cancer: Advances in model systems, microenvironmental influences, therapy, and origins. Front Oncol, 2015, Sep 22;5:205, doi: 10.3389/fonc.2015.00205 [invited editorial].

Hayes SA, Haefliger S, Harris B, Pavlakis N, Clarke SJ, Molloy MP, Howell VM. Exhaled breath condensate for lung cancer protein analysis: A review of methods and biomarkers. Journal of Breath Research, 10(3), 1-26. [034001]. DOI: 10.1088/1752-7155/10/3/034001

Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, Capper D, Specenier P, Rodon J, Cleverly A, Smith C, Gueorguieva I, Miles C, Guba SC, Desaiah D, Lahn MM, Wick W. (2016) A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro Oncol. 18(8):1146-56

Gzell CE, Wheeler HR, McCloud P, Kastelan M, Back M. (2016) Small increases in enhancement on MRI may predict survival post radiotherapy in patients with glioblastoma. J Neurooncol. 128(1):67-74


Ashton, A.W., Le, T.Y.L., Gomez-Sanchez, C.E., Morel-Kopp, C., McWhinney, B., Hudson, A.L., Mihailidou, A.S. (2015) Role of non-genomic signalling pathways activated by aldosterone during cardiac reperfusion injury. Mol Endocrinol, 29, 1144-1155.

Weir, C.J., Hudson, A.L., Peters, L. and Howell, V.M. (2015). Orthotopic implantation and peripheral immune cell monitoring in the II-45 syngeneic rat mesothelioma model. Jove, 104, e53019.

Parker NR, Khong P, Parkinson JF, Howell VM and Wheeler HR. (2015) Molecular heterogeneity in glioblastoma: potential clinical implications. Front. Oncol. eCollection, accepted.

Davis ID, Long A, Yip S, Martin A, Espinoza D, Thompson JF, Kichenadasse G, Harrison M, Lowenthal RM, Pavlakis N, Azad A, Kannourakis G, Steer C, Goldstein D, Shapiro J, Harvie R, Jovanovic L, Hudson AL, Nelson CC, Stockler MR. (2015) EVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first line therapy for advanced renal cell carcinoma. Annals of Oncology, accepted.

Al Khamici H, Brown LJ, Hossain KR, Hudson AL, Sinclair-Burton AA, Ng JP, Daniel EL, Hare JE, Cornell BA, Curmi PM, Davey MW, Valenzuela SM. (2015) Members of the chloride intracellular ion channel protein family demonstrate glutaredoxin-like enzymatic activity. PLoS One, 10, e115699.

Diakos CI, Charles KA, Chua W, Howell VMClarke SJ. (2015) Biomarkers in metastatic colorectal cancer: Predicting prognosis and therapeutic response. In Biomarkers in Disease: Methods, Discoveries and Applications. V.R. Preedy, Ed.; Springer: New York, (ISBN 978-94-007-7681-4)

Kan CWS, Howell VM, Hahn M, Marsh DJ. (2015) Genomic alterations as mediators of miRNA dysregulation in ovarian cancer. Genes, Chromosomes Cancer. 54(1):1-19

Ip JC, Pang TC, Glover AR, Soon P, Zhao JT, Clarke S, Robinson BG, Gill AJ, Sidhu SB. (2015) Immunohistochemical Validation of Overexpressed Genes Identified by Global Expression Microarrays in Adrenocortical Carcinoma Reveals Potential Predictive and Prognostic Biomarkers. Oncologist. 2015 Feb 5. pii: theoncologist.2014-0392. [Epub ahead of print]

Kao SC, van Zandwijk N, Clarke S, Vardy J, Lumba S, Tognela A, Ng W. (2015) Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: An evidence-based benchmark for cancer care. Asia Pac J Clin Oncol. 11(1):85-92.

Zhou J, Belov L, Chapuis P, Chan C, Armstrong N, Kaufman KL, Solomon MJ, Clarke SJ, Christopherson RI. (2015) Surface profiles of live colorectal cancer cells and tumor infiltrating lymphocytes from surgical samples correspond to prognostic categories. J Immunol Methods.416:59-68.

Tan CS, Read JA, Phan VH, Beale PJ, Peat JK, Clarke SJ. (2015) The relationship between nutritional status, inflammatory markers and survival in patients with advanced cancer: a prospective cohort study. Support Care Cancer. 23(2):385-91.

Halkett GK, Lobb EA, Rogers MM, Shaw T, Long AP, Wheeler HR, Nowak AK. (2015) Predictors of distress and poorer quality of life in High Grade Glioma patients. Patient Educ Couns. 98(4):525-32

Back M, Gzell CE, Kastelan M, Guo L, Wheeler HR. (2015) Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma
Neurooncol Pract. 2(1):48-53


Hudson, ALWeir, C, Moon, E, Harvie, R, Klebe, S, Clarke, SJPavlakis, N. and Howell, V.M. (2014) Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. Sci Rep. 4, 6152.

Howell VM. (2014) Mice and men working together for over 100 years in the fight against cancer. Semin Cell Dev Biol. 27:52-3.

Toon CW, Chou A, DeSilva K, Chan J, Patterson J, Clarkson A, Sioson L, Jankova L, Gill AJ. BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. Modern Pathology 2014 27, 644–650

Howell VM and Colvin EK Genetically engineered insertional mutagenesis in mice to model cancer: Sleeping Beauty. Methods Mol Biol. 2014;1194:367-83.

Holt DE, Henthorn P, Howell VM, Robinson BG and Benn DE. (2014) Succinate Dehydrogenase Subunit D (SDHD) and Succinate Dehydrogenase Subunit B (SDHB) Mutation Analysis in Canine Phaeochromocytoma and Paraganglioma. J Comp Pathol. 151(1):25-34.

Fuller, ES. and Howell, VM (2014). Culture Models to Define Key Mediators of Cancer Matrix Remodeling. Front Oncol. 4:57.

Howell VM. (2014) Genetically engineered mouse models for epithelial ovarian cancer: are we there yet? Semin Cell Dev Biol. 27:106-17.

Vardy J, Dhillon HM, Pond GR, Rourke SB, Xu W, Dodd A, Renton C, Park A, Bekele T, Ringash J, Zhang H, Burkes R, Clarke SJ, Tannock IF. (2014) Cognitive function and fatigue after diagnosis of colorectal cancer. Ann Oncol. 25(12):2404-12.

Chik JH, Zhou J, Moh ES, Christopherson R, Clarke SJ, Molloy MP, Packer NH. (2014) Comprehensive glycomics comparison between colon cancer cell cultures and tumours: implications for biomarker studies. J Proteomics. 108:146-62.

Weir, CHudson, AL, Moon E, Ross A, Alexander M, Peters L, Langova V, Clarke SJPavlakis N, Davey R and Howell VM (2014) Streptavidin: A novel immunostimulant for the selection and delivery of autologous and synegenic tumor vaccines. Cancer Immunol Res, 2, 469-79.

Diakos CI, Charles KA, McMillan DC, Clarke SJ. (2014) Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 15(11):e493-503.

Ip JC, Pang TC, Glover AR, Soon P, Clarke S, Richardson A, Campbell P, Robinson BG, Sidhu SB.(2014) Improving Outcomes in Adrenocortical Cancer: An Australian Perspective. Ann Surg Oncol.2014 Oct 16. [Epub ahead of print]

Colvin, EKWeir, CIkin, RJ and Hudson, AL (2014) SV40 TAg mouse models of cancer. Semin Cell Dev Biol, 27C, 61-73.

Sonpavde G, Pond GR, Armstrong AJ, Clarke SJ, Vardy JL, Templeton AJ, Wang SL, Paolini J, Chen I, Chow-Maneval E, Lechuga M, Smith MR, Michaelson MD. (2015) Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 12(5):317-24.

Kao SC, van Zandwijk N, Clarke S. (2014) Comment on ‘Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma’. Br J Cancer.111(12):2376.

Kohonen-Corish MR, Tseung J, Chan C, Currey N, Dent OF, Clarke S, Bokey L, Chapuis PH. (2014) KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer. Int J Cancer. 134(12):2820-8.

Hayes, SAHudson, ALClarke, SJ, Molloy, MP and Howell, VM (2014) From mice to men: GEMMs as trial patients for new NSCLC therapies. Semin Cell Dev Biol, 27C, 118-127.

Paik JY, Toon CW, Benn DE, High H, Hasovits CPavlakis N, Clifton-Bligh RJ, Gill AJ. (2014) Renal carcinoma associated with succinate dehydrogenase B mutation: a new and unique subtype of renal carcinoma. J Clin Oncol. Feb 20;32(6):e10-3.

Khasraw M, Ameratunga MS, Grant R, Wheeler HPavlakis N. (2014) Antiangiogenic therapy for high-grade glioma. Cochrane Database Syst Rev. Sep 22;9:CD008218.

Linton A, Pavlakis N, O’Connell R, Soeberg M, Kao S, Clarke S, Vardy J, van Zandwijk N. (2014) Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer. 111(9):1860-9.

Houang M, Sioson L, Clarkson A, Watson N, Farzin M, Toon CW, Raut A, O’Toole SA, Cooper WA, Pavlakis N, Mead S, Chou A, Gill AJ. (2014) EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer. Pathology. 46(6):501-8.

Price TJ, Segelov E, Burge M, Haller DG, Tebbutt NC, Karapetis CS, Punt CJ, Pavlakis N, Arnold D, Gibbs P, Shapiro JD. (2014) Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. Expert Rev Anticancer Ther.14(12):1477-93.

Ameratunga M, Pavlakis N, Gebski V, Broad A, Khasraw M. (2014) Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis. Asia Pac J Clin Oncol. 10(3):273-8.

Segelov E, Chan D, Shapiro J, Price TJ, Karapetis CS, Tebbutt NC, Pavlakis N. (2014) The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. Br J Cancer. 111(6):1122-31.

Toon CW, Hasovits C, Paik J, Field M, Chou A, Hugh TJ, Pavlakis N, Gill AJ. (2014) Skin rash, a kidney mass and a family mystery dating back to World War II. Med J Aust. 201(1):58-60.

Wong MH, Xue A, Julovi SM, Pavlakis N, Samra JS, Hugh TJ, Gill AJ, Peters L, Baxter RC, Smith RC. (2014) Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma. Clin Cancer Res. 20(15):4047-58.

Lin HM, Castillo L, Mahon KL, Chiam K, Lee BY, Nguyen Q, Boyer MJ, Stockler MR, Pavlakis N, Marx G, Mallesara G, Gurney H, Clarke SJ, Swarbrick A, Daly RJ, Horvath LG. (2014) Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br J Cancer. 110(10):2462-71.

Cooper W, Fox S, O’Toole S, Morey A, Frances G, Pavlakis N, O’Byrne K, Dettrick A, Leong T, Rathi V, Spagnolo D, Hemmings C, Singh M, Moffat D, Tsao MS, Wilner K, Buller R, Pitman Lowenthal S, Arifeen S, Binko J, Alam M. (2014) National Working Group Meeting on ALK diagnostics in lung cancer. Asia Pac J Clin Oncol. 10 Suppl 2:11-7.

Wang F, Gill AJ, Neale M, Puttaswamy V, Gananadha S, Pavlakis NClarke S, Hugh TJ, Samra JS. Adverse tumor biology associated with mesenterico-portal vein resection influences survival in patients with pancreatic ductal adenocarcinoma. Ann Surg Oncol. 21(6):1937-47.

Paik JY, Toon CW, Benn DE, High H, Hasovitz CPavlakis N, Clifton-Bligh RJ, Gill AJ. (2014) Renal carcinoma associated with succinate dehydrogenase B mutation: a new and unique subtype of renal carcinoma. J Clin Oncol. 32(6):e10-3.

Govi S, Christie D, Mappa S, Marturano E, Bruno-Ventre M, Messina C, Medina EA, Porter D, Radford J, Heo DS, Park Y, Pro B, Jayamohan J, Pavlakis N, Zucca E, Gospodarowicz M, Ferreri AJ; International Extranodal Lymphoma Study Group. (2014) The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study). Leuk Lymphoma. 55(8):1796-9.

Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O’Callaghan CJ, Marginean C, Zalcberg JR, Simes J, Moore MJ, Tebbutt NC, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, Van Hazel GA, Lee U, Haq R, Virk S, Tu D, Lorimer IA; NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group. (2014) PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer–results from NCIC CTG/AGITG CO.17. Clin Cancer Res. 20(3):744-53.


Parker NP, Correia N, Crossley B, Buckland ME, Howell VM and Wheeler HR. Correlation of MicroRNA 132  Up-regulation with an  Unfavorable Clinical Outcome in Patients with Primary Glioblastoma Multiforme Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide Chemotherapy. Translational Oncology. 2013 Dec; 6(6), 742-748.

Jankova L, Dent OF, Chan C, Chapuis P, Clarke SJ. Preoperative neutrophil/lymphocyte ratio predicts overall survival but does not predict recurrence or cancer specific survival after curative resection of node-positive colorectal cancer. BMC Cancer. 2013 Oct 1;13(1):442.

Diakos CI, Chua W, Charles, KA, Howell VM and Clarke SJ. Predicting chemotherapeutic response and toxicity in colorectal cancer. Colorectal Cancer 2013 2(4): 333-345.

Stein R, Sharpe L, Boyle F, Dunn S and Clarke SJ. A randomised controlled trial of a structured intervention to facilitate end-of-life decision-making in patients with advanced cancer. J Clin Oncol 2013 31(27): 3403-3410.

Linton A, Pond G, Clarke S, Vardy J, Galsky M and Sonpavde G. Glasgow Prognostic Score as a prognostic factor with metastatic castration-resistant prostate cancer receiving docetaxel-based chemotherapy. Clin Genitourinary Cancer. 2013 Dec 11(4): 423-30

Toon CW, Walsh MJ, Chou A, Dapper D, Clarkson A, Sioson L, Clarke S, Mead S, Walters RJ, Clendenning M, Rosty C Young JP, Win AK, Hopper JL, Crook A, on Deimling A, Jenkins MA, Buchanan DB, Gill AJ. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch Syndrome. Am J Surg Pathol. 2013 Oct;37(10): 1592-602.

Nowak AK, Brown C, Millward MJ, Creaney J, Byrne MJ, Hughes B, Kremmidiotis G, Bibby DC, Leske AF, Mitchell PL, Pavlakis N, Boyer M, Stockler MR A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer. 2013 Sep;81(3):422-7.

Kacevska M, Mahns A, Sharma R, Clarke SJ, Robertson GR, Liddle C. Extra-Hepatic Cancer Represses Hepatic Drug Metabolism Via Interleukin (IL)-6 Signaling.  Pharm Res. 2013 Sep;30(9):2270-8.

Guthrie GJ, Charles KA, Roxburgh CSD, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based Neutrophil-Lymphocyte Ratio: Experience in patients with cancer. Crit Rev Oncol Hematol. 2013 Oct;88(1):218-30.

Tang JZ, Carmichael CL, Shi W, Metcalf D, Ng AP, Hyland CD, Jenkins NA, Copeland NG, Howell VM, Zhao ZJ, Smyth GK, Kile BT, Alexander WS. Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia. Proc Natl Acad Sci USA 2013 110(15):6091-6.

Chang DK, Jamieson NB, Johns AL, Scarlett CJ, Pajic M, Chou A, Pinese M, Humphris JL, Jones MD, Toon C, Nagrial AM, Chantrill LA, Chin VT, Pinho AV, Rooman I, Cowley MJ, Wu J, Mead RS, Colvin EK, Samra JS, Corbo V, Bassi C, Falconi M, Lawlor RT, Crippa S, Sperandio N, Bersani S, Dickson EJ, Mohamed MA, Oien KA, Foulis AK, Musgrove EA, Sutherland RL, Kench JG, Carter CR, Gill AJ, Scarpa A, McKay CJ, Biankin AV. Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol 2013 31(10):1348-56.

Wauters E, Sanchez-Arevalo Lobo VJ, Pinho AV, Mawson A, Herranz D, Wu J, Cowley MJ, Colvin EK, Ngawi Njicop E, Sutherland RL, Liu T, Serrano M, Bouwens L, Real FX, Biankin AV, Rooman I. Sirtuin-1 regulates acinar to ductal metaplasia and supports cancer cell viability in pancreatic cancer. Cancer Research 2013 73(7): 2357-67.

Price TJ, Segelov E, Burge M, Haller DG, Ackland SP, Tebbutt NC, Karapetis CS, Pavlakis N, Sobrero AF, Cunningham D, Shapiro JD. Current opinion on optimal treatment for colorectal cancer. Expert Rev Anticancer Ther. 2013 13(5):597-611.

Buikhuisen WA, Burgers JA, Vincent AD, Korse CM, van Klaveren RJ, Schramel FM, Pavlakis N, Nowak AK, Custers FL, Schouwink JH, Gans SJ, Groen HJ, Strankinga WF, Baas P. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2013 14(6):543-51.

Vickers MM, Karapetis CS, Tu D, O’Callaghan CJ, Price TJ, Tebbutt NC, Van Hazel G, Shapiro JD, Pavlakis N, Gibbs P, Blondal J, Lee U, Meharchand JM, Burkes RL, Rubin SH, Simes J, Zalcberg JR, Moore MJ, Zhu L, Jonker DJ. Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Ann Oncol. 2013 24(4):953-60.

Tebbutt NC, Parry MM, Zannino D, Strickland AH, Van Hazel GA, Pavlakis N, Ganju V, Mellor D, Dobrovic A, Gebski VJ; Australasian Gastro-Intestinal Trials Group (AGITG). Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. Br J Cancer 2013 108(4):771-4.

Kao SC, Vardy J, Chatfield M, Pavlaklis N, Corte P, Clarke CW, van Zandwijk N, Clarke SJ. Validation of prognostic factors in malignant pleural mesothelioma – A retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. Clin Lung Cancer 2013 14; 70-77.

Clarke SJ, Karapetis CS, Gibbs P, Pavlakis N, Desai J, Michael M, Tebbutt NC, Price TJ, Tabernero J. Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. Crit Rev Oncol Hemat 2013 85, 121–135.

Elens L, Nieuweboer A, Clarke SJ, Charles K, de Graan A, Haufroid V, Mathijssen RHJ and van Schaik RHN. (2013) The new CYP3A4 intron 6 SNP (CYP3A4*22) encodes lower CYP3A4 activity, as measured with CYP3A Phenotyping Probes Midazolam and Erythromycin. Pharmacogenomics 14(2):137-49.

Elens L, Nieuweboer A, Clarke SJ, Charles K, de Graan A, Haufroid V, Mathijssen RHJ and van Schaik RHN. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenetics and Genomics 2013 23(3):148-55.

Clarke S, Burge M, Cordwell C, Gibbs P, Reece W and Tebbutt N. An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (AvastinTM) [ASCENT]. BMC Cancer 2013 13(1):120.

Kao SC, Vardy J, Harvie R, Chatfield M, van Zandwijk N, Clarke S and Pavlakis N. Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Support Care Cancer 2013 21: 697-705.

Vardy J, Dhillon HM, Clarke SJ, Olesen I, Leslie F, Warby A, Beith J, Sullivan A, Hamilton A, Beale P, Rittau A and McLachlan A. Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. Springer Plus 2013 2:126.

Kao SC, Clarke SJ, Vardy J, Corte P, Clarke CW, van Zandwijk N. Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales of Australia. Internal Med J 2013 413:402-410.

Kao SC, Lee K, Klebe S, Henderson D, McCaughan B, Vardy J, Clarke S and van Zandwijk N. Excision repair cross complementation group 1 and thymidylate synthase expression in mesothelioma patients. Clin Lung Cancer 2013 14: 164-171.

Kao SC, van Zandwijk N, Corte P, Clarke C, Clarke SJ, Vardy J. Use of cancer therapy at the end of life in malignant pleural mesothelioma patients. Support Cancer Care 2013 21:1879-1884.

Li AE, Li BT, Ng BHK, McCormack S, Vedelago J, Clarke SPavlakis N, Samra J. Diagnostic Accuracy of Imaging Modalities in the Evaluation of Vascular Invasion in Pancreatic Adenocarcinoma: A Meta-Analysis. World Journal of Oncology 2013 4(2):74-82.

With your help we are making a difference

Please select ‘Bill Walsh Cancer Research’ on the ‘Donate to’ drop down menu.

How to Donate